Vertex Pharmaceuticals
As on 06 Sep, 2025 | 01:29 IST
| Open | 397.42 |
| Previous Close | 396.93 |
| Beta | 0.05 |
| High | 402.74 |
| Low | 393.51 |
| TTM EPS See historical trend | 16.94(+7966.67% YoY) |
| 52 Week High | 519.88 |
| 52 Week Low | 362.97 |
| TTM PE See historical trend | 23.39(Average PE) |
| Mkt. Cap ($ Billion) | 102.33 |
| Dividend Yield | -- |
Advanced Chart
*Delayed by 20 seconds
MC Technicals
| Days | |
|---|---|
| 5 | 396.23 |
| 10 | 393.4 |
| 20 | 390.77 |
| 50 | 428.48 |
| 100 | 444.04 |
| 200 | 453.5 |
Returns
| 1 Week | 0.13% | |
| 1 Month | -15.45% | |
| 3 Months | -11.42% | |
| YTD | -1.61% | |
| 1 Year | -19.69% | |
| 3 Years | 40.69% |
Financialsin million $
Peers
| Name | Price ($) | Change% | M.Cap(Billion $) | TTM PE | TTM EPS | DY | 52 wk high/low | Technical Rating | |
|---|---|---|---|---|---|---|---|---|---|
| J&J | 175.46 | -0.75 | 422.38 | 16.73 | 10.49 | 2.88 | 177.67/0.00 | 12.33 | Neutral |
| AbbVie | 207.90 | -0.08 | 366.95 | 17.44 | 11.92 | 4.39 | 210.41/0.00 | 7.73 | Bearish |
| Merck | 83.22 | -1.01 | 211.17 | 26.93 | 3.09 | 2.53 | 85.48/0.00 | 0.24 | Bearish |
| Amgen | 313.69 | 0.42 | 163.24 | 17.49 | 17.42 | 3.52 | 329.72/215.32 | -1.81 | Bearish |
| Gilead Sciences | 112.54 | -1.21 | 140.23 | 16.10 | 6.99 | 3.89 | 115.22/0.00 | 8.07 | Bearish |
Market news
- S&P 500 ends lower as Dell and Nvidia dropAugust 30, 2025 10:46 AM
- Dow notches record high as Wall Street cheers Powell's speechAugust 23, 2025 10:31 AM
- Dow ends higher after UnitedHealth gains, other indexes slip on rate cut uncertaintyAugust 16, 2025 11:08 AM
- Stocks slump on latest tariffs, soft jobs dataAugust 2, 2025 11:55 AM
About the company
Vertex Pharmaceuticals Incorporated is a biotechnology company. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. It offers its products to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. Its CFTR correctors, such as lumacaftor, tezacaftor, and elexacaftor, help CFTR proteins reach the cell surface. It offers pipeline of small molecule medicines in other serious diseases where it has insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases.